CNB Bank’s VanEck Biotech ETF BBH Stock Holding History

CNB Bank’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18	Closed	-$3K	–	495
2021 Q4	$3K	Buy	+18	New	+$3.47K	﹤0.01%	393

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TIA

Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.1B AUM 16.5% 1-Year Est. Return

CNB Bank's BBH Position: Q1 2022 in Review

CNB Bank sold out of VanEck Biotech ETF (BBH) in Q1 2022, closing a stake of 18 shares — an estimated $3K sold.

CNB Bank first reported a position in BBH in Q4 2021 and held it in 1 quarter. The position peaked at $3K in Q4 2021. 115 funds tracked by Wall St. Rank hold BBH as of Q1 2022.

CNB Bank reported no remaining VanEck Biotech ETF position as of Q1 2022 after selling out during the quarter.
CNB Bank sold 18 VanEck Biotech ETF shares in Q1 2022, an estimated $3K.
CNB Bank first reported a position in VanEck Biotech ETF in Q4 2021 and held it in 1 quarter.
CNB Bank's VanEck Biotech ETF position peaked at $3K in Q4 2021.
115 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2022.

Based on CNB Bank's 13F filing for Q1 2022, filed 13 Apr 2022.